` ALA (Arovella Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

ALA
vs
S
S&P/ASX 300

Over the past 12 months, ALA has underperformed S&P/ASX 300, delivering a return of -54% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
ALA vs S&P/ASX 300

Loading
ALA
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ALA vs S&P/ASX 300

Performance Gap Between ALA and AXKO
HIDDEN
Show

Performance By Year
ALA vs S&P/ASX 300

Loading
ALA
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Arovella Therapeutics Ltd vs Peers

S&P/ASX 300
ALA
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Arovella Therapeutics Ltd
Glance View

Market Cap
90.3m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
HIDDEN
Show
Back to Top